FDA clears Trinity's AMAX haemostasis analyser:
This article was originally published in Clinica
Trinity Biotech has received US FDA marketing clearance for its AMAX Destiny haemostasis analyser, an instrument which the company claims allows it to target an additional segment of the $700m haemostasis market. The system offers high-end technology on a small, low cost platform, giving smaller clinical laboratories the ability to process haemostasis tests formerly offered only in large reference laboratories, says the Bray, Ireland-based firm. The product offers the flexibility to perform both optical and mechanical clot, chromogenic and immunoturbidimetric- based assays simultaneously.